| Last Sale Price | $ |
|---|---|
| Volume | |
| Market Cap | $410,434,304 |
| Best bid # | |
| Best bid |
Is Mmed a good stock to buy?
Mind Medicine (MindMed) has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Will Mind Medicine stock go up?
On average, analysts give MNMD a Strong Buy rating. The average price target is $8, which means analysts expect the stock to gain by 633.94% over the next twelve months. That average ranking earns MNMD an Analyst Rating of 74, which is better than 74% of stocks based on data compiled by InvestorsObserver.
What is Mmed ne?
Mind Medicine (MindMed) Inc. ( NASDAQ: MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today reported its financial results for the quarter ended March 31, 2022.
Why is Mmed stock going down?
Summary. The recent decline in MindMed's share price is a result of changes to the broader macroeconomic landscape. The FDA just approved MindMed's IND application, inducing a spike in the company's shares. Still, MindMed is down 67% in the past year.
Could Mind Medicine Be a Millionaire Maker stock?
Yes, but with the chance of great reward comes substantial risk.
What happened MindMed stock?
As MindMed's (NASDAQ: MNMD, NEO: MMED) stock has tumbled over the past year —the company is down an astonishing 82% since June 2021— fear of a Nasdaq delisting among retail investors has spread like wildfire.
What does mind medicine do?
Mind Medicine Inc., also known as MindMed, is a New York-based psychedelic medicine biotech company that develops psychedelic-inspired medicines known as psychoplastogens and therapies to address addiction and mental illness.
Where is mind medicine located?
New York, NYDescription Mind Medicine (MindMed) Inc. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn in 2019 and is headquarter in New York, NY.
Where is MindMed located?
New York, New YorkMindMed is located in New York, New York, United States .
Where can I buy Mmedf stocks?
Shares of MMEDF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
When did MNMD go public?
April 27th, 2021On Tuesday, April 27th, 2021, the MindMed stock started trading on the Nasdaq Capital Market. On the Nasdaq, the stock trades under the ticker symbol MNMD.
What is Mmedf stock?
NASDAQ › MIND MEDICINE MINDMED INC. (NASDAQ:MMEDF) 4.69 +1.17 (+24.95%)
Ideas
Possible Entry bouncing on resist, I Will see if we go threw 2.82. If reject , 1.64 is next buy zone for me... Actually sliding down the channel. Bounce is expected...
Profile
Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Scott M.
What is MindMed?
MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading clinical stage psychedelic medicine company, and Nextage Therapeutics (TASE: NXTG), an Israeli innovative drug development company , announce the execution of a Memorandum of Understanding (the "MOU") regarding the launch of an exclusive collaborative development program to optimize the delivery of certain psychedelic drug candidates, leveraging Nextage's proprietary Brain Targeting Liposome System (BTLS) delivery technology, for which it has an exclusive license. MindMed and Nextage will initially collaborate to optimize the delivery of drug products based on noribogaine, and ultimately other ibogaine derivatives, and will share development costs and intellectual property arising from the collaboration.
When will MindMed be added to Russell 3000?
MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic-inspired medicine company announced that effective Friday, June 25th, 2021, MindMed has been added to the FTSE Russell 3000® index which measures the performance of the largest 3,000 US companies.
Where is MindMed conducted?
The study will be conducted at the University Hospital Basel Liechti Lab, in Basel, Switzerland , and is planned to start this month.
